Work

Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer

Year: 2022

Type: article

Study design: Observational Study

Source: Journal of Thoracic and Cardiovascular Surgery

DOI: 10.1016/j.jtcvs.2022.10.056

Authors: Harry B. Lengel, Junting Zheng, Kay See Tan, Corinne C. Liu, Bernard J. Park, Gaetano Rocco, Prasad S. Adusumilli, Daniela Molena, Helena A. Yu, Gregory J. Riely, Manjit S. Bains, Valerie W. Rusch, Mark G. Kris, Jamie E. Chaft, Bob T. Li, James M. Isbell, David R. Jones

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, F. Hoffmann-La Roche, Memorial Sloan-Kettering Cancer Center, Intuitive Surgical, National Institutes of Health, Genentech, National Cancer Institute

Awards: G2272812018, G2761881728, G289723095, G757714940, G790026694, BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma, G9000096403, Cancer Center Support Grant

OpenAlex ID: W4309172008

FWCI: 1.264

Cites: 54

Cited by: 9

Related to: 10